Named Bioactive Compounds · Compound
Aescin
Moderate Evidencesaponin
Hermetica Superfood Encyclopedia
Aescin is a triterpene saponin compound extracted from horse chestnut seeds that demonstrates significant efficacy for chronic venous insufficiency. It works by strengthening venous walls, reducing inflammation, and improving circulation through anti-edematous and venotonic mechanisms.
Aescin (also known as escin) is the major active principle extracted from the seeds of Aesculus hippocastanum (horse chestnut tree), belonging to the chemical class of triterpene saponins, primarily beta-aescin isomers. It is obtained through extraction methods from horse chestnut seed extract (HCSE) and has been used in traditional European medicine.
Clinical evidence includes a controlled trial demonstrating aescin's effectiveness for chronic venous insufficiency comparable to compression therapy (PMID: 11529685), and a phase II trial (n=240) showing potential benefits in advanced thyroid cancer with improved progression-free and overall survival. Randomized controlled trials have confirmed significant improvements in venous refilling time and reduction in post-injury tenderness with topical applications.
Oral: Horse chestnut seed extract standardized to aescin content (specific mg varies by product). Intravenous: 0.2-0.6 mg/kg/day for up to 9 days studied in cancer patients. Topical: 1-2% escin gels applied to affected areas. Consult a healthcare provider before starting any new supplement.
Aescin (also spelled escin) is a purified triterpene saponin mixture extracted primarily from horse chestnut (Aesculus hippocastanum) seeds, not a dietary nutrient or food ingredient. It is not characterized by macronutrients, micronutrients, vitamins, minerals, or fiber content. As a bioactive compound, its profile is defined by its chemical composition: a complex mixture of acylated triterpene glycosides, predominantly β-aescin (the pharmacologically active fraction, ~60-70% of total aescin) and α-aescin (~30-40%). β-Aescin itself comprises two principal isoforms, aescin Ia and aescin Ib, differing in ester linkage positions. The molecular weight of the primary components ranges approximately 1100-1150 g/mol. Aescin is amphiphilic due to its saponin structure (hydrophilic sugar moieties: glucuronic acid, glucose, galactose attached to a hydrophobic aglycone protoaescigenin or barringtogenol C backbone). Typical therapeutic oral doses used in clinical trials are 50-150 mg/day of β-aescin (standardized extract). Bioavailability is notably limited: oral bioavailability is estimated at approximately 5-15% due to poor gastrointestinal absorption and first-pass metabolism; delayed-release formulations improve this marginally. Topical formulations typically contain 1-2% aescin w/w. The compound exhibits surface-active (detergent-like) properties at higher concentrations. No meaningful caloric, protein, fat, or carbohydrate contribution is associated with therapeutic doses.
Aescin strengthens capillary walls by stabilizing endothelial cells and reducing vascular permeability through inhibition of hyaluronidase and elastase enzymes. The compound enhances venous tone by increasing norepinephrine sensitivity in venous smooth muscle and reducing inflammatory prostaglandin E2 production. Beta-aescin, the primary active component, also exhibits anti-edematous effects by normalizing capillary filtration and improving lymphatic drainage.
A controlled trial (PMID: 11529685) demonstrated that oral aescin therapy was equally effective as compression stockings for chronic venous insufficiency treatment. A randomized controlled trial showed 168% improvement in venous refilling time after 14 days of supplementation (p<0.0001). Multiple studies support topical aescin formulations for reducing localized edema and inflammation, though most trials involve relatively small sample sizes of 50-100 participants. Evidence is strongest for venous disorders, with moderate-quality clinical data supporting its efficacy.
Aescin is generally well-tolerated with mild gastrointestinal upset being the most common side effect at therapeutic doses of 100-150mg daily. The compound may enhance anticoagulant medications like warfarin due to its anti-platelet properties, requiring monitoring of bleeding parameters. Topical applications rarely cause contact dermatitis or allergic reactions in sensitive individuals. Pregnancy and breastfeeding safety data is insufficient, making supplementation inadvisable during these periods.
